DC Medical develops and commercializes innovative medical devices, including a portable diagnostic device that uses Electrical Impedance Spectroscopy (EIS) technology with the goal to detect the chance of premature birth for mothers.
deepmedi is developing and providing smartphone sensor-based health information estimation technology through deep learning and image processing.
While the implications of the pandemic are still unfolding, countries across the world are preparing for life in the “New Normal.”
In this period of transition, forward-thinking innovations aiming to address healthcare challenges are needed more than ever. Through disruption, we must leverage data and health technologies to accelerate potentially life-saving ideas aiming to improve patient care through the uncharted times that lay ahead.
That is why Johnson & Johnson Innovation—JLABS (“JLABS”), in collaboration with Seoul Metropolitan Government (“SMG”), Korea Health Industry Development Institute (“KHIDI”), Janssen Korea Ltd., is launching the Seoul Innovation QuickFire Challenge for Healthcare in the New Normal.
Up to two innovators with the best ideas aiming to address and enable potential healthcare solutions in the post-COVID era will receive up to KRW150,000,000 (approximately US$125,000) in grant funding, residency at the Seoul Bio Hub, and mentorship and coaching from experts at the Johnson & Johnson Family of Companies.
 From the KRW150 million grant, each awardee will receive a KRW75 million grant including one-year mandatory residency, which must be used toward the rent and utilities at the Seoul Bio Hub for a year. Estimate based on exchange rate of 0.00083 in June 2020
Areas of Interest
We encourage applications from innovators working on all aspects of health care within the “New Normal.” This includes:
Specifically, we’re looking for:
- Health technologies including big data, artificial intelligence, and block chain
- E-health platforms that can improve the patient journey, empowering decision making for physicians and leading to better patient outcomes
- Rapid diagnostics for early detection and monitoring of rare diseases – in particular for Pulmonary Hypertension (PH)
- Companion diagnostics for oncology
- Smart systems for vaccine distribution and patient adherence
We are interested in applications seeking to impact:
- Patient care & shared decision making
- Healthcare related problem solving, including impact that aims to lower cost and improves access to car
- Customized approach for better outcomes
- One-year residency at the Seoul Bio Hub
- A year of mentorship and coaching from experts in science and commercialization at the Johnson & Johnson Family of Companies
- Access to programming & resources from the Johnson & Johnson Innovation – JLABS ecosystem
*From the KRW 150 million grant, each awardee will receive a KRW 75 million grant including one-year mandatory residency, which must be used toward residency at the Seoul Bio Hub for a year.
*South Korean won equals 0.00083 United States Dollar
Why this challenge matters to us
We believe a good idea can come from anywhere, and it’s our goal to find new and innovative technologies that provide solutions to patients from around the world. Working together, we can spark the next great idea that could change the trajectory of health. Seoul, Korea has a robust healthcare innovation ecosystem and Johnson & Johnson is aiming to accelerate breakthroughs through this QuickFire Challenge.
What is being awarded and to how many innovators/companies?
Up to two awardees will be awarded up to KRW150,000,000 (approximately US$125,000) in grant funding, one year of residency at the Seoul Bio Hub, one year of mentorship and coaching from experts in science and commercialization at the Johnson & Johnson Family of Companies, and access to the JLABS global entrepreneurial community.
Where do I apply?
You can apply through http://jnjawards.fluidreview.com.
What if I’m having trouble accessing the portal/website?
Make sure your browser is up to date and accepting cookies. You can contact customer service at [email protected]/ if you are having technical difficulties.
What does residency at the Seoul Bio Hub entail?
For this challenge, residency at the Seoul Bio Hub entails the entitlement to rent an office suite at Seoul Bio Hub and around. From the KRW150 million grant, each awardee will receive a KRW75 million grant including one-year mandatory residency which must be used toward the rent and utilities at the Seoul Bio Hub for a year.
For prizes involving residency, are there any expenses not covered by the Seoul Bio Hub?
Each awardee will be responsible for its monthly rent and utilities. Each awardee will receive a grant, including one year of rent and utilities at the Seoul Bio Hub. Please contact the Seoul Bio Hub ([email protected]) for more information on the rental cost.
Will JLABS or Seoul Bio Hub pay for my living costs, relocation or visas?
No, any additional fees and paperwork are the responsibility of the awardee.
Can I submit supporting documents (for example a video) as part of my application?
You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is two minutes.
Is it ok if some of the information I submit is confidential?
Do not submit confidential information. Only non-confidential information should be submitted and anything you submit will be treated as non-confidential.
What happens with IP (Intellectual Property)?
As this is a no-strings-attached arrangement, JLABS does not acquire any IP. Any IP creation and/or protection remains the sole responsibility of the inventors.
Is a patent required to apply?
No, a patent is not required to apply. However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.
What kind of science / technology is appropriate for the Challenges?
We encourage all to apply. Find out more about what areas we desire to explore here: https://www.jnjinnovation.com/partnering.
Who is eligible to apply?
Applicants may be individuals, entrepreneurs, academics, biotech researchers or an early-stage company that is less than 60 months old. Each Challenge has its own terms & conditions that can be found prior to filling out the application.
What are the specific criteria for application?
Submissions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:
- Potential impact
- Uniqueness of solution & level of competition in current market
- Quality & feasibility of technology
- Team credibility & capabilities
- Plans for utilizing the Seoul Bio Hub
- Idea submission outlines interest in the innovation ecosystem in Seoul
Do applicants have to reside in Korea in order to apply?
No, this is a global challenge. However, if selected as an awardee or finalist, at least one core team member of the applicant company must reside in the Seoul Bio Hub for no less than one year.
Who can I contact if I have questions about the Challenges or the application process?
Please contact [email protected] with any questions.
Where do I apply? And do I have to complete the application in one sitting?
You can setup an account at http://jnjawards.fluidreview.com. You are able to save your work and log back in to finish at a later time if needed.
About Johnson & Johnson Innovation
Johnson & Johnson Innovation, LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers; Johnson & Johnson Innovation – JLABS; Johnson & Johnson Innovation – JJDC, Inc.; and our business development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. JLABS provides the laboratories, expertise, education, tools and resources needed to help life science startups thrive, all with no strings attached. A Johnson & Johnson Innovation Center for Device Innovation at the Texas Medical Center (CDI @ TMC) has been established to accelerate the development of medical devices. For more information about Johnson & Johnson Innovation, please visit: www.jnjinnovation.com.
About Johnson & Johnson Innovation - JLABS
Johnson & Johnson Innovation - JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer and health tech sectors to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS, we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS also produces campaigns to seek out the best science called QuickFire Challenges. For more information, visit www.jlabs.jnjinnovation.com or follow @JLABS.
About the Seoul Metropolitan Government
Seoul is a global city located at the center of Northeast Asia characterized by easy access to metropolitan cities around the world and convenient living conditions, with 24 subway lines, 590 subway stations, 6,068 bus stops, and 13 international schools.
Seoul is an optimal location to foster technology-oriented venture firms as it houses more than 20,000 research institutes, 88 universities, and 58 general hospitals, concentrating top-caliber workforce and technology in a single location.
The Hongneung Biomedical Cluster, home to Seoul Bio Hub, opened in October 2017, houses national research institutes (KIST, etc.), research-oriented hospitals, and universities. The Seoul Metropolitan Government offers facilities and equipment for the fast growth of technologically advanced startups and helps businesses, researchers, and businessmen develop and commercialize innovative technologies via support in investment, administration, and information services.
About Seoul Bio Hub
Seoul Bio Hub, located in northern Seoul began operations in October 2017 and is a life science innovation center sponsored by SMG and operated by KHIDI. Its key function is to support early-stage life science companies’ growth and commercialization by providing full-service wet laboratory and office spaces, shared equipment, networking events, training programs, and investor relation opportunities. As the only biotech startup platform located in Seoul, it leverages its geographical advantages to accelerate the startup ecosystem, by facilitating cooperative networks among research-driven hospitals, universities, national research institutes, and venture capital firms within close proximity. For more information, please visit http://www.seoulbiohub.kr.
About Korea Health Industry Development Institute (KHIDI)
KHIDI is a government-affiliated institution that provides professional and systems-building support aimed at developing the domestic healthcare industry and enhancing healthcare services. Since its establishment in 1999, KHIDI has led the expansion of healthcare research and development investment within the region, helping to build the competitiveness of Korea's healthcare industry across health services, pharmaceuticals, medical devices, food and beauty-cosmetics. KHIDI is designated as an operating body of the Seoul Bio Hub and is leveraging its infrastructure and network to facilitate collaborations with relevant stakeholders to advance scientific innovation. For more information, please visit http://www.khidi.or.kr/eps.
About Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com.